Overview

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

Status:
NOT_YET_RECRUITING

Trial end date:
2028-11-06

Target enrollment:

Participant gender:

Summary

To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC

Phase:

PHASE1

Details

Lead Sponsor:

Akeso

Collaborator:

Fudan University

Treatments:

Injections